At its IPO on May 14, 2026, Cerebras Systems stock was priced at $185 per share and closed the first day of trading at about $311. CBRS reached its all-time high of $386.34 on May 14 and its all-time low of $77.84 on November 5. As of November 13, the stock had climbed back to around $109, still more than 70% below its first-day close.

Then Q3 earnings arrived, and the picture shifted.

The Business

Cerebras makes wafer-scale AI processors, chips designed to run AI inference faster than conventional GPU clusters by processing across an entire silicon wafer rather than individual dies. Cerebras reported third-quarter core revenue of $230.9 million, up 70% from a year earlier, and raised its full-year revenue outlook. The core revenue beat topped the $214.7 million analyst consensus, and adjusted earnings of 12 cents per share came against an expected loss of 14 cents. Inside the Q3 core revenue figure, core cloud and other services revenue was $144.9 million, an increase of 272% year over year.

Why Wall Street Is Paying Attention

The AI chipmaker said it recently signed a deal with hyperscaler Microsoft. CEO Andrew Feldman told CNBC the deal was signed in October 2026 and that revenue is expected to begin showing up in Q1 2027. Cerebras also reported commercial wins with two new hyperscalers and 700 megawatts of data center capacity now under contract. Cerebras raised its 2026 revenue forecast to $940 million to $960 million and reported $26.1 billion of remaining performance obligations as of September 30, 2026, much of it tied to its OpenAI relationship. Q4 2026 core revenue was guided to approximately $310 million to $330 million, above the $271 million LSEG estimate. Cerebras also said it expects to triple revenue in 2027.

The Microsoft deal matters more because of what Azure has already demonstrated. Microsoft’s AI business reaching a $37 billion annual revenue run rate suggests hyperscaler demand for inference capacity is real and still accelerating.

What Could Go Wrong

The GAAP net loss came to $161.2 million, or 67 cents per share. The valuation, roughly $26 billion in market cap against trailing twelve-month revenue of about $756 million, leaves no margin for error. Cerebras’s final 180-day lock-up release date was November 9, 2026, making previously restricted shares eligible to trade. That introduces fresh selling pressure from early holders. The OpenAI deal is where the concentration risk sits. A large portion of the $26.1 billion in remaining performance obligations runs through one relationship, and Microsoft revenue does not arrive until 2027. If either timeline slips or hyperscaler spending softens, the stock has room to revisit its November lows.

Concentration risk and lock-up pressure are not unique to Cerebras. Debt markets have largely shut off access to AI infrastructure financing for companies without revenue independent of a single hyperscaler relationship.

The Bottom Line

According to 11 analysts, the average rating for CBRS stock is “Strong Buy” with a 12-month price target of $225.64, an increase of more than 100% from the latest price. Management says the company exceeded guidance across the board for the third quarter in a row and delivered sequential improvements on all core financial metrics. The question is not whether the business is real. The question is whether execution over the next two quarters matches the ambition of the 2027 revenue triple. At $109, the market is not paying much for the benefit of the doubt, and that is precisely what makes it worth considering today.